|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Peritoneal carcinomatosis of colorectal origin:Incidence,prognosis and treatment options显示文摘Peritoneal carcinomatosis (PC) is one manifestation of metastatic colorectal cancer (CRC). Tumor growth on intestinal surfaces and associated fluid accumulation eventually result in bowel obstruction and incapacitating levels of ascites, which profoundly affect the quality of life for affected patients. PC appears resistant to traditional 5-fluorouracil-based chemotherapy, and surgery was formerly reserved for palliative purposes only. In the absence of effective treatment, the histori-cal prognosis for these patients was extremely poor, with an invariably fatal outcome. These poor outcomes likely explain why PC secondary to CRC has received little attention from oncologic researchers. Thus, data are lacking regarding incidence, clinical disease course, and accurate treatment evaluation for patients with PC. Recently, population-based studies have revealed that PC occurs relatively frequently among patients withCRC. Risk factors for developing PC have been identi-fied:right-sided tumor, advanced T-stage, advanced N-stage, poor differentiation grade, and younger age at diagnosis. During the past decade, both chemother-apeutical and surgical treatments have achieved prom-ising results in these patients. A chance for long-term survival or even cure may now be offered to selected patients by combining radical surgical resection with intraperitoneal instillation of heated chemotherapy. This combined procedure has become known as hy-perthermic intraperitoneal chemotherapy. This edito-rial outlines recent advancements in the medical and surgical treatment of PC and reviews the most recent information on incidence and prognosis of this disease. Given recent progress, treatment should now be considered in every patient presenting with PC. | Yvonne LB Klaver Valery EPP Lemmens Simon W Nienhuijs Misha DP Luyer Ignace HJT de Hingh | 2012 | World Journal of Gastroenterology2012，18，39： | 9 |
| 2 | Current application of proteomics in biomarker discoveryfor inflammatory bowel disease显示文摘Recently, the field of proteomics has rapidly expanded in its application towards clinical research with objectives ranging from elucidating disease pathogenesis to discovering clinical biomarkers. As proteins govern and/or reflect underlying cellular processes, the study of proteomics provides an attractive avenue for research as it allows for the rapid identification of protein profiles in a biological sample. Inflammatory bowel disease(IBD) encompasses several heterogeneous and chronic conditions of the gastrointestinal tract. Proteomic technology provides a powerful means of addressing major challenges in IBD today, especially for identifying biomarkers to improve its diagnosis and management. This review will examine the current state of IBD proteomics research and its use in biomarker research. Furthermore, we also discuss the challenges of translating proteomic research into clinically relevant tools. The potential application of this growing field is enormous and is likely to provide significant insights towards improving our future understanding and management of IBD. | Patrick PY Chan Valerie C Wasinger Rupert W Leong | 2016 | World Journal of Gastrointestinal Pathophysiology2016，7，1： | 5 |
| 3 | Gene and cell therapy based treatment strategies for inflammatory bowel diseases显示文摘Inflammatory bowel diseases(IBD)are a group of chronic inflammatory disorders most commonly affecting young adults.Currently available therapies can result in induction and maintenance of remission,but are not curative and have sometimes important side effects.Advances in basic research in IBD have provided new therapeutic opportunities to target the inflammatory process involved.Gene and cell therapy approaches are suitable to prevent inflammation in the gastrointestinal tract and show therefore potential in the treatment of IBD.In this review,we present the current progress in the field of both gene and cell therapy and future prospects in the context of IBD.Regarding gene therapy,we focus on viral vectors and their applications in preclinical models.The focus for cell therapy is on regulatory T lymphocytes and mesenchymal stromal cells,their potential for the treatment of IBD and the progress made in both preclinical models and clinical trials. | Sander van der Marel Anna Majowicz Sander van Deventer Harald Petry Daniel W Hommes Valerie Ferreira | 2011 | World Journal of Gastrointestinal Pathophysiology2011，2，6： | 3 |
| 4 | Comparison of the efficacy and safety of rosuvastatin versus atorvastatin , simvastatin , and pravastatin across doses (STELLAR * * STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)显示文摘 | Peter H Jones Michael H Davidson Evan A Stein Harold E Bays James M McKenney Elinor Miller Valerie A Cain James W Blasetto | 2003 | The American Journal of Cardiology2003，，2： | 2 |
| 5 | Experimen- tal therapeutics, preclinical pharmacology experimental therapeu- tics with a new 10-deazaaminopterin in human mesothelioma: Fur- ther improving efficacy through structural design, pharmacologic modulation at the Level of MRP ATPases, and combined therapy with Platinums显示文摘 | NUSHMIA Z K YUHONG S VALERIE W R | 2001 | Clin Cancer Res2001，7，10： | 1 |
| 6 | Lomaivitieins A and B, potent antitumor antibiotics from Micromonospora lomaivitiensis 显示文摘 | He H Ding W W Valerie S B | 2001 | J Am Chem Soc2001，123，22： | 1 |
| 7 | Limb activation and the rehabilitation of unilateral neglect:evidence of task-specific effects显示文摘 | Valerie B Robin W Chria G | 1999 | Neurocase1999，5，： | 1 |
| 8 | A pulse system for spectrum analysis of magnetoelastic biosensors显示文摘 | SHEN W LESLIE C M VALERY A P | 2010 | Applied Physics Letters2010，96，16： | 1 |
| 9 | How CLIP became ECLIPSE:a mnemonic to assist in searching for health policy/management information显示文摘 | Valerie W Bell L | 2002 | Health Information and Library Journal2002，19，2： | 1 |
| 10 | Acylation of N-p-tolue- nesulfonylpyrrole under Friedel-Crafts conditions: evi- dence for organoaluminum intermediates 显示文摘 | John W Huffman Valerie J | 2008 | Tetrahed- ron2008，64，： | 1 |
| 11 | Cassini star tracking and identification architecture显示文摘 | Valerie C Thomas James W Alexander | 2000 | Proceedings of SPIE2000，2221，： | 1 |
| 12 | Modifiable Factors Associated With Improved Cardiac Arrest Survival in a Multicenter Basic Life Support/Defibrillation System: OPALS Study Phase I Results显示文摘 | Ian G Stiell George A Wells Valerie J DeMaio Daniel W Spaite Brian J Field Douglas P Munkley Marion B Lyver Lorraine G Luinstra Roxanne Ward | 1999 | Annals of Emergency Medicine1999，，： | 1 |
| 13 | The impact of complications on outcomes after resection for esophageal and gastroesophageal junction carcinoma显示文摘 | Nabil P Rizk Peter B Bach Deborah Schrag Manjit S Bains Alan D Turnbull Martin Karpeh Murray F Brennan Valerie W Rusch | 2004 | Journal of the American College of Surgeons2004，，1： | 1 |
| 14 | Requirement of macrophages and eosinophils and their cytokines/chemokines for mammary gland development显示文摘 | Valerie G E LIn E Y Pollard J W | 2002 | Breast Cancer Research2002，4，： | 1 |
| 15 | Induction chemoradiation and surgical resecticn for Non-small-cell Lung Carcinosis of the superior sulcus:initial results of southwest oncology group trial 416显示文摘 | Valerie W Rusch MD Dorothy J | 2001 | The Journal of Thoraeic and Cardiovascular Surgery2001，121，： | 1 |
| 16 | Limb activation and the rehabil itation of unilateral neglect: evidence of task specific effects显示文摘 | Valerie B Robin W Chris G | 1999 | Neurocase1999，5，： | 1 |
| 17 | Limb activation and the rehabilitation of unilateral neglect: evidence of task-specific effects显示文摘 | Valerie B Robin W Chris G | 1999 | Neurocase1999，5，： | 1 |
| 18 | The effect of vitamin E on blood pressure in individuals with type 2 diabetes: a randomized, double-blind, placebo-controlled trial显示文摘 | Natalie C Ward Jason HY Wu Michael W Clarke Ian B Puddey Valerie Burke Kevin D Croft Jonathan M Hodgson | 2007 | Journal of Hypertension2007，，1： | 1 |
| 19 | Comparison of the efficacy and safety of rosuvastatin versus atorvastatin , simvastatin , and pravastatin across doses (STELLAR * * STELLAR = Statin Therapies for Elevated Lipid Levels compared Across doses to Rosuvastatin. Trial)显示文摘 | Peter H Jones Michael H Davidson Evan A Stein Harold E Bays James M McKenney Elinor Miller Valerie A Cain James W Blasetto | 2003 | The American Journal of Cardiology2003，，2： | 1 |
| 20 | Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report显示文摘BACKGROUND A variety of immune-modulating drugs are becoming increasingly used for various cancers. Despite increasing indications and improved efficacy, they are often associated with a wide variety of immune mediated adverse events including colitis that may be refractory to conventional therapy. Although these drugs are being more commonly used by Hematologists and Oncologists, there are still many gastroenterologists who are not familiar with the incidence and natural history of gastrointestinal immune-mediated side effects, as well as the role of infliximab in the management of this condition.CASE SUMMARY We report a case of a 63-year-old male with a history of metastatic renal cell carcinoma who presented to our hospital with severe diarrhea. The patient had received his third combination infusion of the anti-CTLA-4 monoclonal antibody Ipilimumab and the immune checkpoint inhibitor Nivolumab and developed severe watery non-bloody diarrhea the same day. He presented to the hospital where he was found to be severely dehydrated and in acute renal failure. An extensive workup was negative for infectious etiologies and he was initiated on high dose intravenous steroids. However, he continued to worsen. A colonoscopy was performed and revealed no endoscopic evidence of inflammation. Random biopsies for histology were obtained which showed mild colitis, and were negative for Cytomegalovirus and Herpes Simplex Virus. He was diagnosed with severe steroid-refractory colitis induced by Ipilimumab and Nivolumab and was initiated on Infliximab. He responded promptly to it and his diarrhea resolved the next day with progressive resolution of his renal impairment. On follow up his gastrointestinal side symptoms did not recur.CONCLUSION Given the increasing use of immune therapy in a variety of cancers, it is important for gastroenterologists to be familiar with their gastrointestinal side effects and comfortable with their management, including prescribing infliximab. | Ammar B Nassri Valery Muenyi Ahmad AlKhasawneh Bruno De Souza Ribeiro James S Scolapio Miguel Malespin Silvio W de Melo Jr | 2019 | World Journal of Gastrointestinal Pharmacology and Therapeutics2019，10，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员